Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

October 16, 2019October 16, 2019

Bone Defects Detected at Birth, After Injury, in Mouse Models of Hemophilia A and B, Study Shows

News

Bone defects were seen since birth — and following injury — in mouse models of hemophilia A and B, but not in Von Willebrand (VWD) disease mice, a study ... Read more

October 4, 2019October 4, 2019

DalcA, Under-skin Injectable Factor IX Prophylactic, Showing Potential in Phase 2 Trial, Catalyst Says

News

A preventive treatment for hemophilia B called dalcinonacog alfa (DalcA) led to an increase of more than 12% in the levels of factor IX in two patients with severe disease treated in ... Read more

September 13, 2019September 13, 2019

Freeline’s Gene Therapy for Hemophilia B Is Promising, Phase 1/2 Data Show

News

Data from the first two patients treated with FLT180a, Freeline’s single-infusion gene therapy for patients with hemophilia B, showed a rise in levels of clotting factor IX to 40%, with ... Read more

August 28, 2019August 28, 2019

FDA Grants Sigilon Therapeutic’s SIG-001 Orphan Drug Status for Hemophilia A

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Sigilon Therapeutics’ candidate cell therapy, called SIG-001, for hemophilia A. Orphan drug status aims to encourage therapies for rare and ... Read more

August 14, 2019August 14, 2019

Variations in Certain Immune Genes May Help Predict Risk for Developing FVIII Inhibitors in Hemophilia A

News

Genetic variations in certain immune-related genes, namely the HLA and IL-10 genes, are linked with an increased risk for developing inhibitors against factor VIII replacement therapies in patients with ... Read more

August 5, 2019August 5, 2019

Parent’s Sense of Burden Higher When Child Overweight and Has Inhibitors, Study Finds

News

The presence of inhibitors and excessive body weight increase the sense of disease burden felt by parents of children with moderate to severe hemophilia, a study reports. The study ... Read more

July 19, 2019July 19, 2019

Two-stage Gene Therapy for Hemophilia A Shows Promising Results in Mice, Researchers Say

News

Casebia’s two-stage gene therapy approach was successful in delivering the human gene coding for clotting factor VIII (FVIII) in a mouse model of hemophilia A, leading to stable and ... Read more

July 8, 2019July 8, 2019

Vaccination of Hemophilia Patients Varies in Germany and Should Be Reassessed to Minimize Fear, Survey Suggests

News

Recommendations for vaccination practices for patients with hemophilia should be reassessed in an effort to minimize fear and emphasize the importance of vaccination to prevent infections, suggests a survey ... Read more

July 1, 2019July 1, 2019

Higher FVIII Blood Levels Seen and Better Maintained with Jivi Than Eloctate, Phase 1 Study in Severe Hemophilia A Finds

News

Bayer’s Jivi, an FVIII replacement therapy for hemophilia A, has a longer half-life and a slower clearance from blood circulation than Eloctate, and may protect against bleeding for longer periods, ... Read more

May 31, 2019May 31, 2019

BioMarin’s Gene Therapy for Severe Hemophilia Yields Sustained Benefit, Data Show

News

BioMarin Pharmaceutical’s investigative gene therapy, called valoctocogene roxaparvovec, is capable of sustained control of bleeding rate requiring factor VIII infusions by at least 92% in adults with severe hemophilia A, ... Read more

Pin It on Pinterest